Japan CRO Business Reports 15 Percent Revenue Increase In 2007
This article was originally published in PharmAsia News
Executive Summary
The Japan Contract Research Organization Association reports that total revenue of its members increased by 15 percent, to ¥95.5 billion, in 2007 due largely to growth in the monitoring business. JCRO President Kazuo Nakamura said that growth for 2008 will be in the double digits, too. Nakamura, chairman of Tokyo-based CMIC Co., also estimates Japan's CRO market will exceed the ¥100 billion mark. As a next step, JCRO will start a monitor certifying system as early as this year. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.